Discuss your application with an expert
Physiologically relevant human and preclinical animal species models better predict adverse drug-induced effects to reduce risk in the clinic
Current industry methods
Simple cell culture systems lack physiological complexity and animal models are poor predictors of drug safety in humans. This limits the extrapolation of data from these systems to human safety toxicology.
Many drugs with clean preclinical toxicity profiles will produce adverse effects in human trials leading to costly late-stage withdrawals and potential harm to study participants. Conversely, false positive results may cause the termination of potential blockbusters unnecessarily.
Advancements with PhysioMimix®
PhysioMimix Core organ-on-a-chip models recreate in vivo physiology and function in vitro. They provide a human-specific mechanistic understanding of potential drug toxicity in healthy and diseased organ models and the ability to compare data to commonly used preclinical animal species in vitro equivalents.
Data derived from these models complement traditional approaches by flagging potential adverse effects in humans and inter-species inconsistencies in response. PhysioMimix’s insights enable issues to be addressed earlier in the pipeline to de-risk drug development.
Drug-induced liver injury
Adverse drug reactions are a major clinical problem, and the liver is one of the most susceptible organs to drug toxicity.
Our drug-induced liver injury (DILI) assays assess the toxicity of a wide range of entities (small molecules, protein, ASOs, AAVs, etc) in the presence or absence of liver disease.
They facilitate more informed predictions of human (and preclinical animal species) liver responses to acute and repeat drug exposure using a broad spectrum of clinically translatable endpoints.
Immune-mediated liver injury
Predicting immune-mediated, or idiosyncratic toxicity is challenging because of the complexity of the immune system, limited understanding of the underlying mechanisms, and a lack of suitable models.
Our immunocompetent organ-on-a-chip models can provide data on the reaction mechanisms that determine how inflammation influences drug-induced toxicity from e.g. monoclonal antibodies.
Customer adapted applications
Drug-induced
Charles River
Genotoxicity
Pharmaron
Gastrointestinal toxicity
Pharmaron
Pulmonary toxicity
Texax A&M
Nephrotoxicity
We adopted Organ-on-a-chip (OOC), or microphysiological systems (MPS), technology into Charles River to enhance our assay to achieve more human-relevant outcomes for genetic toxicology assessments. We believed that we can achieve this goal by using OOC/MPS with human cells.
Annie Hamel
Scientific Director, Genetic Toxicology – Charles River Laboratories
Chemical-induced
The goal was to build a multi‑omics pipeline capable of measuring complex biological responses to chemicals with known toxicity. The ultimate aim is to translate these insights into a next‑generation risk‑assessment tool that could inform regulatory decision‑making
Dr Emma Arnesdotter
Luxembourg Institute of Science and Technology (LIST)
